Strata Critical Medical, Inc.

NASDAQ:SRTA

Airlines, Airports & Air Services

Industrials
$4.96 -0.43%

-$0.03 today

Market cap
$443.03M
Beta
2.20
P/E (TTM)
9.7
EPS (TTM)
$0.60
52W Low $3.57High $6.50

Volume 0.99M

Average 0.91M

SRTA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Strata Critical Medical, Inc.NASDAQ: SRTA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $1.12M rose 37.7% year over year, ahead of the +25.8% change in trailing-twelve-month research & development. Sequentially, it fell 34.2% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.

Context

  • Research & development amounted to 1.5% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +37.7% holds above the trailing-twelve-month pace of +25.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.12M-34.2% QoQ
Last fiscal yearDec 2025
$3.05M-4.1% YoY
LTMMar 2026
$4.18M+25.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.7%——
1 year-4.1%——
3-year CAGR-18.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
3.05M USD
Year-over-year change
-4.1%
4-year CAGR
+16.0%

Research & Development vs competitors

How SRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +25.8% is the 2nd highest of 4, against a peer median of +0.7%.
  • Research & development amounts to 1.6% of revenue for SRTA, versus a peer median of 0.0%.
SRTA Competitors
Research & Development for SRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AIROAIRO Group Holdings, Inc. Common StockLTM Mar 2026$16.01B USD+136110.5%+24.4%18184.8%
ZIPZipRecruiter, Inc.LTM Mar 2026$117.38M USD-11.1%-0.8%26.3%
EVTLVertical Aerospace Ltd.LTM Mar 2026£106.28M GBP—+13.6%—
CYRXCryoport, Inc.LTM Mar 2026$17.01M USD+0.7%+0.4%9.3%
SRTAStrata Critical Medical, Inc.LTM Mar 2026$4.18M USD+25.8%-18.0%1.6%
KFRCKforce Inc.LTM Mar 2026$0 USD——0.0%
EBFEnnis, Inc.LTM Feb 2026$0 USD——0.0%
ULHUniversal Logistics Holdings, Inc.LTM Apr 2026$0 USD——0.0%
ORNOrion Group Holdings, Inc.LTM Mar 2026$0 USD——0.0%
MTRXMatrix Service CompanyLTM Mar 2026$0 USD——0.0%
FLYXflyExclusive, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SRTA) —+0.7%+7.0%0.0%

Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue50.53M146.12M225.18M248.69M197.14M
Cost of Revenue40.01M123.85M183.06M189.77M158.82M
Gross Profit10.52M22.28M42.12M58.92M38.33M
Gross Margin20.8%15.2%18.7%23.7%19.4%
Research & Development1.68M5.55M4.63M3.18M3.05M
Selling, General & Admin32.93M70.26M105.61M89.66M45.08M
Operating Expenses34.61M75.8M110.24M92.85M48.13M
Depreciation & Amortization596K5.73M7.11M5.96M6.9M
EBITDA(43.1M)(22.31M)(50.43M)(21.6M)(13.17M)
EBITDA Margin-85.3%-15.3%-22.4%-8.7%-6.7%
Operating Income(24.09M)(53.53M)(68.12M)(33.93M)(9.81M)
Operating Margin-47.7%-36.6%-30.3%-13.6%-5.0%
Interest Income460K3.43M8.44M7.21M4.24M
Interest Expense00000
Other Income / Expenses(19.6M)25.5M10.58M6.36M(10.26M)
Income Before Tax(43.7M)(28.03M)(57.54M)(27.56M)(20.07M)
Pre-Tax Margin-86.5%-19.2%-25.6%-11.1%-10.2%
Income Tax Expense(3.64M)(772K)(1.47M)(255K)0
Net Income(40.05M)(27.26M)(56.08M)(27.31M)(15.65M)
Net Margin-79.3%-18.7%-24.9%-11.0%-7.9%
EPS (Basic)(0.57)(0.38)(0.76)(0.35)(0.19)
EPS (Diluted)(0.57)(0.38)(0.76)(0.35)(0.19)
Weighted Avg Shares70.1M71.24M73.52M77.5M82.45M
Weighted Avg Shares (Diluted)70.1M71.24M73.52M77.5M82.45M

Strata Critical Medical, Inc.

NASDAQ:SRTA

Intrinsic Alpha fair value

Locked

Current Price

$4.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.